Exenatide BID (Amylin, now Bristol-Myers Squibb, New York, NY, USA), a synthetic form of exendin-4 with a terminal half-life of ~2.4 h, in 2005 was the first GLP-1 RA approved for the treatment of type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.